NCT02320318View on ClinicalTrials.gov

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Ibodutant 10 mg

Oral tablet, once daily.

DRUG

Placebo

Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.

Trial Locations (20)

104

Taipei

333

Taoyuan District

640

Yunlin

704

Tainan City

807

Kaohsiung City

10002

Taipei

11217

Taipei

40201

Taichung

83301

Kaohsiung City

110744

Seoul

137701

Seoul

138736

Seoul

200704

Gangwon-do

258500

Singapore

308433

Singapore

463712

Gyeonggi-do

471701

Gyeonggi-do

529889

Singapore

602739

Busan

705718

Daegu

Sponsors

Lead Sponsor

Menarini Group
All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT02320318 - 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Biotech Hunter | Biotech Hunter